| Alhemo (concizumab) / Novo Nordisk |
| Active, not recruiting | 3 | 136 | Europe, Japan, US, RoW | Concizumab | Novo Nordisk A/S | Haemophilia A With Inhibitors, Haemophilia B With Inhibitors | 12/21 | 02/27 | | |
|
|
2020-000504-11: A research study on how well concizumab works for you if you have haemophilia A or B with or without inhibitors (explorer10) Studio clinico per capire se concizumab funziona bene per te se hai l’emofilia A o B con o senza inibitori (explorer10) |
|
|
| Ongoing | 3 | 96 | Europe, RoW | Concizumab C 40 mg/mL PDS290, Concizumab C 10 mg/mL PDS290, Concizumab C 100 mg/mL PDS290, [NN7415], Solution for injection in pre-filled pen | NOVO NORDISK. S.P.A., Novo Nordisk A/S, , Novo Nordisk A/S | Haemophilia A with or without inhibitorsHaemophilia B with our without inhibitors Emofilia A con o senza inibitoriEmofilia B con o senza inibitori, Bleeding disorder, inherited deficiency in clotting factor VIII or IX with or without antibodies to replacement therapy Disturbi emorragici, deficienza ereditaria del fattore VIII o IX della coagulazione con o senza anticorpi per la terapia sostitutiva, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
| Active, not recruiting | 3 | 158 | Europe, Canada, Japan, US, RoW | Concizumab | Novo Nordisk A/S | Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors | 07/22 | 06/26 | | |
|
|
| Recruiting | 3 | 90 | Europe, Canada, Japan, US, RoW | Concizumab | Novo Nordisk A/S, , Novo Nordisk A/S | Haemophilia A and B With and Without Inhibitors | 12/24 | 11/29 | | |
GLAT, NCT06234813: Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study |
|
|
| Completed | N/A | 20 | Europe | Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen, : PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM, Thrombin Generation Assay (TGA) in PRP using TF trigger, Global fibrinolytic capacity in PRP using reagents for in vitro triggering of the clot and its lysis, Concizumab | University Hospital, Bordeaux | Glanzmann Thrombasthenia | 07/23 | 07/23 | | |
NCT04921956: Compassionate Use of Concizumab if You Have Haemophilia |
|
|
| Available | N/A | | Europe, US | Concizumab | Novo Nordisk A/S | Congenital Haemophilia | | | | |
NCT05617209: In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients |
|
|
| Recruiting | N/A | 20 | Europe | thrombin generation measurement | Centre Hospitalier Universitaire de Saint Etienne | Hemophilia | 12/23 | 12/23 | | |
NN7415-7557, NCT06285071: Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors |
|
|
| Enrolling by invitation | N/A | 23 | Japan | Concizumab, Alhemo | Novo Nordisk A/S | Haemophilia A, Haemophilia B | 04/30 | 04/30 | | |
